Source comparison
Is Tesamorelin Better Than Egrifta: Clinical Comparison
Active Molecule Tesamorelin acetate (44 amino acids) Identical peptide sequence. No molecular difference FDA Approval Status FDA-approved drug product Compounded under 503B or state pharmacy oversight. Not FDA-approved as finished product Egrifta has full regu
This comparison does not assign a generated winner or score.
- Active Molecule
- Tesamorelin acetate (44 amino acids)
- Identical peptide sequence. No molecular difference
- FDA Approval Status
- FDA-approved drug product
- Compounded under 503B or state pharmacy oversight. Not FDA-approved as finished product
- Egrifta has full regulatory approval; compounded versions do not
- Cost per Month
- $5,000–$6,000 (before insurance)
- $200–$600 (typical retail)
- Compounded versions cost 60–85% less
- Quality Assurance
- cGMP manufacturing, batch traceability, FDA oversight
- Dependent on compounding facility. Ranges from rigorous (503B with third-party testing) to unverifiable (offshore suppliers)
- Branded guarantees consistency; compounded quality varies by source
- Insurance Coverage
- Covered for HIV-lipodystrophy indication (with prior authorization)
- Not covered. Out-of-pocket only
- Insurance only applies to on-label Egrifta use
- Clinical Evidence
- Phase 3 trial data (EGRIFTA-003, EGRIFTA-004)
- Same molecule. Clinical mechanism identical, but no independent trial data for compounded formulations
- Mechanism is the same; trial validation applies to the peptide, not the brand